Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells

Biomedicine and Pharmacotherapy

Volumn 62, Issue 10, 2008, Pages 723-729

  Lee, Shin Hwa ^a   Park, Cheol ^b   Jin, Cheng Yun ^b   Kim, Gi Young ^c   Moon, Sung Kwon ^d   Hyun, Jin Won ^e   Lee, Won Ho ^b   Choi, Byung Tae ^b   Kwon, Taeg Kyu ^f   Yoo, Young Hyun ^g   Choi, Yung Hyun ^b,h  

^a Korea Science Academy   (South Korea)

^b Pusan National University   (South Korea)

^c Jeju National University   (South Korea)

^d Chungju National University   (South Korea)

^e Jeju National University School of Medicine   (South Korea)

^f Keimyung University   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Dong Eui University   (South Korea)

Author keywords

ERK; Esculetin; G1 arrest; p21; pRB; U937

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; ESCULETIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; E2F1 TRANSCRIPTION FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; U937 CELLS; UMBELLIFERONES;

EID: 56249116987     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.12.001     Document Type: Article

References (29)

1. Koff A., Giordano A., Desai D., Yamashita K., Harper J.W., Elledge S., et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 272 (1992) 1689-1694
2. Morgan D. Cyclin dependent kinases: Engines, clocks and microprocessors. Annu Rev Cell Dev Biol 13 (1997) 261-291
3. Elledges S.J., and Harper J.W. Cdk inhibitor: on the threshold of checkpoints and development. Curr Opin Cell Biol 6 (1994) 847-852
4. Sandal T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist 7 (2002) 73-81
5. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
6. Kyosseva S.V. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59 (2004) 201-220
7. Chang F., Steelman L.S., Shelton J.G., Lee J.T., Navolanic P.M., Blalock W.L., et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 22 (2003) 469-480
8. Sang S., Hou Z., Lambert J.D., and Yang C.S. Redox properties of tea polyphenols and related biological activities. Antioxid Redox Signal 7 (2005) 1704-1714
9. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 428 (1999) 305-327
10. Tubaro A., Del Negro P., Ragazzi E., Zampiron S., and Della Loggia R. Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. Pharmacol Res Commun 20 (1998) 83-85
11. Huang H.C., Lai M.W., Wang H.R., Chung Y.L., Hsieh L.M., and Chen C.C. Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways. Eur J Pharmacol 237 (1993) 39-44
12. Matsumoto E., Hatanaka M., Bohgaki M., and Maeda S. PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells. Kobe J Med Sci 52 (2006) 181-194
13. Hecht S.S., Kenney P.M., Wang M., Trushin N., Agarwal S., Rao A.V., et al. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137 (1999) 123-130
14. Martin-Aragon S., Benedi J.M., and Villar A.M. Effects of the antioxidant (6,7-dihydroxycoumarin) esculetin on the glutathione system and lipid peroxidation in mice. Gerontology 44 (1998) 21-25
15. Lin W.L., Wang C.J., Tsai Y.Y., Liu C.L., Hwang J.M., and Tseng T.H. Inhibitory effect of esculetin on oxidative damage induced by t-butyl hydroperoxide in rat liver. Arch Toxicol 74 (2000) 467-472
16. Neichi T., Koshihara Y., and Murota S. Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim Biophys Acta 753 (1983) 130-132
17. Hofmanova J., Soucek K., Pachernik J., Kovarikova M., Hoferova Z., Minksova K., et al. Lipoxygenase inhibitors induce arrest of tumor cells in S-phase of the cell cycle. Neoplasma 49 (2002) 362-367
18. Wang C.J., Hsieh Y.J., Chu C.Y., Lin Y.L., and Tseng T.H. Inhibition of cell cycle progression in human leukemia HL-60 cells by esculetin. Cancer Lett 183 (2002) 163-168
19. Yang J.Y., Della-Fera M.A., and Baile C.A. Esculetin induces mitochondria-mediated apoptosis in 3T3-L1 adipocytes. Apoptosis 11 (2006) 1371-1378
20. Pan S.L., Huang Y.W., Guh J.H., Chang Y.L., Peng C.Y., and Teng C.M. Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. Biochem Pharmacol 65 (2003) 1897-1905
21. Kuo H.C., Lee H.J., Hu C.C., Shun H.I., and Tseng T.H. Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol 210 (2006) 55-62
22. Park C., Choi B.T., Cheong J., Moon S.K., Kim C.H., Lee W.H., et al. Induction of apoptosis and G2/M arrest by N-methyl-N′-nitro-N-nitrosoguanidine in human prostate carcinoma cells. Mutat Res 563 (2004) 139-149
23. Danova M., Giordano M., Mazzini G., and Riccardi A. Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk Res 14 (1990) 417-422
24. DeGregori J., Leone G., Ohtani K., Miron A., and Nevins J.R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev 9 (1995) 2873-2887
25. Hsu Y.F., Lee T.S., Lin S.Y., Hsu S.P., Juan S.H., Hsu Y.H., et al. Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells. Mol Carcinog 46 (2007) 275-283
26. Villedieu M., Briand M., Duval M., Heron J.F., Gauduchon P., and Poulain L. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression. Gynecol Oncol 105 (2007) 373-384
27. Zhu H., Zhang L., Wu S., Teraishi F., Davis J.J., Jacob D., et al. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK. Oncogene 23 (2004) 4984-4992
28. Park K.S., Ahn Y., Kim J.A., Yun M.S., Seong B.L., and Choi K.Y. Extracellular zinc stimulates ERK-dependent activation of p21(Cip/WAF1) and inhibits proliferation of colorectal cancer cells. Br J Pharmacol 137 (2002) 597-607
29. Beier F., Taylor A.C., and LuValle P. The Raf-1/MEK/ERK pathway regulates the expression of the p21(Cip1/Waf1) gene in chondrocytes. J Biol Chem 274 (1999) 30273-30279